25.1364.01000
Sixty-ninth
SENATE BILL NO. 2370
Legislative Assembly
of North Dakota
Introduced by
Senators Cleary, Dever, Mathern
Representative McLeod
1 A BILL for an Act to create and enact a new section to chapter 26.1-36 of the North Dakota
2 Century Code, relating to individual and group health insurance coverage of insulin drugs and
3 supplies; and to amend and reenact section 54-52.1-04.18 of the North Dakota Century Code,
4 relating to health insurance benefits coverage of insulin drugs and supplies.
5 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:
6 SECTION 1. A new section to chapter 26.1-36 of the North Dakota Century Code is created
7 and enacted as follows:
8 Health insurance benefits coverage - Insulin drug and supply out - of-pocket
9 limitations.
10 1. As used in this section:
11 a. "Insulin drug" means a prescription drug that contains insulin and is used to treat
12 a form of diabetes mellitus. The term does not include an insulin pump, an
13 electronic insulin-administering smart pen, or a continuous glucose monitor, or
14 supplies needed specifically for the use of such electronic devices. The term
15 includes insulin in the following categories:
16 (1) Rapid-acting insulin;
17 (2) Short-acting insulin;
18 (3) Intermediate-acting insulin;
19 (4) Long-acting insulin;
20 (5) Premixed insulin product;
21 (6) Premixed insulin/GLP - 1 RA product; and
22 (7) Concentrated human regular insulin.
23 b. "Medical supplies for insulin dosing and administration" means supplies needed
24 for proper insulin dosing, as well as supplies needed to detect or address medical
Page No. 1 25.1364.01000

Sixty-ninth
Legislative Assembly
1 emergencies in an individual using insulin to manage diabetes mellitus. The term
2 does not include an insulin pump, an electronic insulin-administering smart pen,
3 or a continuous glucose monitor, or supplies needed specifically for the use of
4 such electronic devices. The term includes:
5 (1) Blood glucose meters;
6 (2) Blood glucose test strips;
7 (3) Lancing devices and lancets;
8 (4) Ketone testing supplies, such as urine strips, blood ketone meters, and
9 blood ketone strips;
10 (5) Glucagon, in injectable and nasal forms;
11 (6) Insulin pen needles; and
12 (7) Insulin syringes.
13 c. "Pharmacy or distributor" means a pharmacy or medical supply company, or
14 other medication or medical supply distributor filling a prescription.
15 2. An insurance company, nonprofit health service corporation, or health maintenance
16 organization may not deliver, issue, execute, or renew any health insurance policy,
17 health service contract, or evidence of coverage on an individual, group, blanket,
18 franchise, or association basis unless the policy, contract, or evidence of coverage
19 provides benefits for insulin drug and medical supplies for insulin dosing and
20 administration which complies with this section.
21 3. The health benefit plan must limit ou t - of-pocket costs for a thirty - day supply of :
22 a. Covered insulin drugs, which may not exceed twenty-five dollars per pharmacy or
23 distributor, regardless of the quantity or type of insulin drug used to fill the
24 covered individual's prescription needs.
25 b. Covered medical supplies for insulin dosing and administration, the total of which
26 may not exceed twenty-five dollars per pharmacy or distributor, regardless of the
27 quantity or manufacturer of supplies used to fill the covered individual's
28 prescription needs.
29 4. The health benefit plan may not allow a pharmacy benefits manager or the pharmacy
30 or distributor to charge, require the pharmacy or distributor to collect, or require a
31 covered individual to make a payment for a covered insulin drug or medical supplies
Page No. 2 25.1364.01000

Sixty-ninth
Legislative Assembly
1 for insulin dosing and administration in an amount exceeding the ou t - of-pocket limits
2 under subsection 3 .
3 5. The health benefit plan may not impose a deductible, copayment, coinsurance, or
4 other cost-sharing requirement that causes ou t - of-pocket costs for prescribed insulin
5 or medical supplies for insulin dosing and administration to exceed the amount under
6 subsection 3 .
7 6. Subsection 3 does not require the health benefit plan to implement a particular cost-
8 sharing structure and does not prevent the limitation of ou t - of-pocket costs to less than
9 the amount specified under subsection 3. This section does not limit whether the
10 health benefit plan classifies an insulin pump, an electronic insulin-administering smart
11 pen, or a continuous glucose monitor as a drug or as a medical device or supply.
12 7. If application of subsection 3 would result in the ineligibility of a health benefit plan tha t
13 is a qualified high-deductible health plan to qualify as a health savings account under
14 section 223 of the Internal Revenue Code [26 U.S.C. 223], the requirements o f
15 subsection 3 do not apply with respect to the deductible of the health benefit plan unti l
16 after the enrollee has met the minimum deductible under section 26 U.S.C. 223.
17 8. This section does not apply to the Medicare par t D prescription drug coverage plan .
18 SECTION 2. AMENDMENT. Section 54-52.1-04.18 of the North Dakota Century Code is
19 amended and reenacted as follows:
20 54-52.1-04.18. Health insurance benefits coverage - Insulin drug and supply out-of-
21 pocket limitations. (Expired effective July 31, 2025)
22 1. As used in this section:
23 a. "Insulin drug" means a prescription drug that contains insulin and is used to treat
24 a form of diabetes mellitus. The term does not include an insulin pump, an
25 electronic insulin-administering smart pen, or a continuous glucose monitor, or
26 supplies needed specifically for the use of such electronic devices. The term
27 includes insulin in the following categories:
28 (1) Rapid-acting insulin;
29 (2) Short-acting insulin;
30 (3) Intermediate-acting insulin;
31 (4) Long-acting insulin;
Page No. 3 25.1364.01000

Sixty-ninth
Legislative Assembly
1 (5) Premixed insulin product;
2 (6) Premixed insulin/GLP-1 RA product; and
3 (7) Concentrated human regular insulin.
4 b. "Medical supplies for insulin dosing and administration" means supplies needed
5 for proper insulin dosing, as well as supplies needed to detect or address medical
6 emergencies in an individual using insulin to manage diabetes mellitus. The term
7 does not include an insulin pump, an electronic insulin-administering smart pen,
8 or a continuous glucose monitor, or supplies needed specifically for the use of
9 such electronic devices. The term includes:
10 (1) Blood glucose meters;
11 (2) Blood glucose test strips;
12 (3) Lancing devices and lancets;
13 (4) Ketone testing supplies, such as urine strips, blood ketone meters, and
14 blood ketone strips;
15 (5) Glucagon, in injectable and nasal forms;
16 (6) Insulin pen needles; and
17 (7) Insulin syringes.
18 c. "Pharmacy or distributor" means a pharmacy or medical supply company, or
19 other medication or medical supply distributor filling a covered individual's
20 prescriptions.
21 2. The board shall provide health insurance benefits coverage that provides for insulin
22 drug and medical supplies for insulin dosing and administration which complies with
23 this section as provided under section 1 of this Ac t.
24 3. The coverage must limit out-of-pocket costs for a thirty-day supply of:
25 a. Covered insulin drugs which may not exceed twenty-five dollars per pharmacy or
26 distributor, regardless of the quantity or type of insulin drug used to fill the
27 covered individual's prescription needs.
28 b. Covered medical supplies for insulin dosing and administration, the total of which
29 may not exceed twenty-five dollars per pharmacy or distributor, regardless of the
30 quantity or manufacturer of supplies used to fill the covered individual's
31 prescription needs.
Page No. 4 25.1364.01000

Sixty-ninth
Legislative Assembly
1 4. The coverage may not allow a pharmacy benefits manager or the pharmacy or
2 distributor to charge, require the pharmacy or distributor to collect, or require a
3 covered individual to make a payment for a covered insulin drug or medical supplies
4 for insulin dosing and administration in an amount that exceeds the out-of-pocket limits
5 set forth under subsection 3.
6 5. The coverage may not impose a deductible, copayment, coinsurance, or other cost-
7 sharing requirement that causes out-of-pocket costs for prescribed insulin or medical
8 supplies for insulin dosing and administration to exceed the amount set forth under
9 subsection 3.
10 6. Subsection 3 does not require the coverage to implement a particular cost-sharing
11 structure and does not prevent the limitation of out-of-pocket costs to less than the
12 amount specified under subsection 3. Subsection 3 does not limit out-of-pocket costs
13 on an insulin pump, an electronic insulin-administering smart pen, or a continuous
14 glucose monitor. This section does not limit whether coverage classifies an insulin
15 pump, an electronic insulin-administering smart pen, or a continuous glucose monitor
16 as a drug or as a medical device or supply.
17 7. If application of subsection 3 would result in the ineligibility of a health benefit plan that
18 is a qualified high-deductible health plan to qualify as a health savings account under
19 section 223 of the Internal Revenue Code [26 U.S.C. 223], the requirements of
20 subsection 3 do not apply with respect to the deductible of the health benefit plan until
21 after the enrollee has satisfied the minimum deductible under section 26 U.S.C. 223.
22 8. This section does not apply to the Medicare part D prescription drug coverage plan.
Page No. 5 25.1364.01000

[DELETED: .A.")R)S)I)L)P) )C."12]
[DELETED: )B)B)L)K)G)I)I.".A. .C.C.T22]
[DELETED: .T. . . .A.")R)S)I)L32]
[DELETED: )P)P)C.")B)B)L)K)G)I)I.".T.T.C.C42]
[DELETED: .T.T.S.I.T52]